CDK inhibitors in cancer therapy: what is next?

Trends in Pharmacological Sciences

Volumn 29, Issue 1, 2008, Pages 16-21

  Malumbres, Marcos ^a   Pevarello, Paolo ^a   Barbacid, Mariano ^a   Bischoff, James R ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AG 024322; AG 24322; ANTINEOPLASTIC AGENT; AT 7519; BAY 80 3000; BAY 803000; CISPLATIN; CY 202; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; FLAVOPIRIDOL; FLUOROURACIL; GPC 286199; JNJ 7706621; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; P 27600; P276 00; R 547; RO 4584820; UNCLASSIFIED DRUG; ZK 304709;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 37549036250     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.10.012     Document Type: Article

References (40)

1. Malumbres M., and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30 (2005) 630-641
2. Malumbres M., and Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1 (2001) 222-231
3. Ciemerych M.A., and Sicinski P. Cell cycle in mouse development. Oncogene 24 (2005) 2877-2898
4. Schang L.M. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim. Biophys. Acta 1697 (2004) 197-209
5. Monaco III E.A., and Vallano M.L. Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease. Front. Biosci. 10 (2005) 143-159
6. Soos T.J., et al. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases. Drug News Perspect. 19 (2006) 325-328
7. Rossi A.G. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 12 (2006) 1056-1064
8. Byrd J.C., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 15 (2007) 399-404
9. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (2006) 1770-1783
10. Misra R.N. Clinical progress of selective cyclin-dependent kinase (CDK) inhibitors. Drugs of the Future 31 (2006) 43-52
11. Castoldi R.E., et al. Assessing and managing toxicities induced by kinase inhibitors. Curr. Opin. Drug Disc. Dev. 10 (2007) 53-57
12. Illanes O., et al. Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin-dependent kinase (CDK) inhibitor in mice. Toxicol. Pathol. 34 (2006) 243-248
13. Andreeff M., et al. Cell proliferation and differentiation. In: Kufe D.W., et al. (Ed). Cancer Medicine 7 (2006), BC Decker Inc. 27-40
14. Kelland L.R. Cyclin-dependent kinase inhibitors and combination therapy: experimental and clinical status. In: Smith P.J., and Yue E.W. (Eds). Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents (2007), CRC Press 371-388
15. Ortega S., et al. Cyclin dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35 (2003) 25-31
16. Berthet C., et al. Cdk2 knockout mice are viable. Curr. Biol. 13 (2003) 1775-1785
17. Rane S.G., et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat. Genet. 22 (1999) 44-52
18. Kip1 activity. Mol. Cell. Biol. 19 (1999) 7011-7019
19. Malumbres M., et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118 (2004) 493-504
20. Berthet C., et al. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev. Cell 10 (2006) 563-573
21. Barrière C., et al. Mice thrive without Cdk4 and Cdk2. Mol. Oncol. 1 (2007) 72-83
22. Santamaría D., et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448 (2007) 811-815
23. Yu Q., et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9 (2006) 23-32
24. Landis M.W., et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9 (2006) 13-22
25. Malumbres M., and Barbacid M. Is Cyclin D1/CDK4 kinase a bona-fide cancer target?. Cancer Cell 9 (2006) 2-4
26. Baughn L.B., et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent linase 4/6. Cancer Res. 66 (2006) 7661-7667
27. Sanatamaria D., et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448 (2007) 811-815
28. Goga A., et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13 (2007) 820-827
29. Cai D., et al. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 66 (2006) 9270-9280
30. Larochelle S., et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol. Cell 25 (2007) 839-850
31. Fedorov O., et al. Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discov. Today 12 (2007) 365-372
32. Joshi K.S., et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol. Cancer Ther. 3 (2007) 918-925
33. Siemeister G., et al. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed. Pharmacother. 60 (2006) 269-272
34. Graham, J. et al. (2006) Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle. In ASCO Annual Meeting Proceedings Part I: 2006 June 2-6; Atlanta. Vol. 24 (18S) (June 20 Supplement), Abstract 2073
35. Ahmed, S. et al. (2006) Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle. In ASCO Annual Meeting Proceedings Part I: 2006 June 2-6; Atlanta. Vol. 24 (18S) (June 20 Supplement), Abstract 2076
36. Chu X.J., et al. Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-yl-amino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl) methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J. Med. Chem. 49 (2006) 6549-6560
37. Lin R., et al. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors : synthesis and evaluation of biological activities. J. Med. Chem. 48 (2005) 4208-4211
38. Emanuel S., et al. The in vitro and in vivo effects of JNJ-7706621: a dual inihibitor of cyclin-dependent kinases and Aurora kinases. Cancer Res. 65 (2005) 9038-9046
39. Caligiuri M., et al. A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression. Chem. Biol. 12 (2005) 1103-1115
40. Verma S., et al. Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 1973-1977